A somatic multiple myeloma mutation unravels a mechanism of oligomerization‐mediated product inhibition in GGPPS
The FEBS Journal · 2025
DOI: 10.1111/febs.70181 ↗At a glance
Journal article in The FEBS Journal, 2025. Written by Ruba Yehia and 7 co-authors. Institution: Department of Physiology and Pharmacology, Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Israel. Major MEDLINE topics: Multiple Myeloma, Mutation, Farnesyltranstransferase. Cited 4 times so far (Crossref); 58 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Israel Cancer Research Fund, Israel Cancer Association, United States-Israel Binational Science Foundation.
Abstract (original language)
Protein prenylation plays a critical role in regulating the cellular localization of small GTPases and is essential for multiple myeloma (MM) pathology. Geranylgeranyl diphosphate synthase (GGPPS), producing a key prenylation moiety, exists in a dimeric or hexameric form, depending on the species. However, the functional significance of this oligomerization remains unclear. Using crystallography, mass spectrometry, and fluorescence spectroscopy, we show that the GGPPS R235C mutant—found in the widely studied MM cell line RPMI‐8226—exhibits weakened inter‐dimer interactions, reduced hexamer stability, and increased apparent substrate affinity and product release kinetics. These effects are even more pronounced in a dimeric mutant, GGPPS Y246D , demonstrating that interdimer interactions within the hexamer help stabilize a lid region over the active site, thereby stabilizing product binding in an inhibitory conformation. Together, these findings reveal that hexamerization regulates GGPPS activity through product inhibition and underscore the importance of cell line selection and characterization in drug discovery efforts.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Physiology and Pharmacology, Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Israel.
- Division BioCeV, Institute of Microbiology of the Czech Academy of Sciences, Vestec, Czech Republic.
- Department of Biochemistry, Faculty of Science, Charles University, Prague 2, Czech Republic.
- BLAVATNIK CENTER for Drug Discovery, Tel Aviv University, Israel.
- Tel Aviv Sourasky Medical Center, Israel.
- Sagol School of Neuroscience, Tel Aviv University, Israel.
ORCID profiles: Alan Kádek, Moshe Giladi, Yoni Haitin
Funding
- Israel Cancer Research Fund
- Israel Cancer Association
- United States-Israel Binational Science Foundation
- Israel Science Foundation
- Ministerstvo Školství, Mládeže a Tělovýchovy
Cite
APA
Yehia, R., Portašiková, J. M., Mor Yosef, R., Da'adoosh, B., Kádek, A., Man, P., Giladi, M., & Haitin, Y. (2025). A somatic multiple myeloma mutation unravels a mechanism of oligomerization‐mediated product inhibition in GGPPS. The FEBS Journal. https://doi.org/10.1111/febs.70181
Vancouver
Yehia R, Portašiková JM, Mor Yosef R, Da'adoosh B, Kádek A, Man P, et al. A somatic multiple myeloma mutation unravels a mechanism of oligomerization‐mediated product inhibition in GGPPS. The FEBS Journal. 2025. doi:10.1111/febs.70181
BibTeX
@article{Yehia2025,
author = {Yehia, Ruba and Portašiková, Jasmína Mária and Mor Yosef, Rut and Da'adoosh, Benny and Kádek, Alan and Man, Petr and Giladi, Moshe and Haitin, Yoni},
title = {A somatic multiple myeloma mutation unravels a mechanism of oligomerization‐mediated product inhibition in GGPPS},
journal = {The FEBS Journal},
year = {2025},
doi = {10.1111/febs.70181}
}
EUVIMED